

A comparison of brief and standard cognitive behavioural therapy (CBT) for patients in palliative care

Submission date 18/10/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 13/01/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 23/05/2016	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims.

Cognitive behaviour therapy (CBT) has been shown to be an effective psychological treatment for distressed patients receiving end of life (palliative) care. But only half of the patients who receive this treatment are well enough to complete treatment which may last 8-12 sessions or more. This study is a randomised controlled trial comparing a specially designed, brief (4 session CBT) with standard CBT (8+ sessions) in people with advanced cancer with anxiety and depression.

Who can participate?

Patients attending St Christophers Hospice who have a diagnosis of advanced cancer and have been referred for psychological therapy because of anxiety or depression will be able to participate.

What does the study involve?

Patients will complete some questionnaires measuring anxiety, depression and coping during an interview with a nurse researcher. After this they will be allocated at random to one of the two treatments. If they receive the brief treatment they will meet a therapist on four occasions and will be helped to work through a self help book that will support the one to one therapy. Their partner will be invited to attend one of the sessions to find out ways they might be able to help. The standard treatment does not use the self help material but focused more on one to one therapy. Both treatments involve cognitive behaviour therapy which is based on the idea that when we become depressed or anxious we focus on the most negative aspects of our situation, become critical of ourselves, and forget our strengths. This unhelpful thinking can make us feel even more hopeless and often leads to withdrawal or avoidance of situations that could make us feel better.

What are the possible benefits and risks of participating?

CBT helps people find more helpful ways of thinking and acting to cope with the stress of life threatening illness. There are no known risks associated with participating in this study.

Where is the study run from?

South London and Maudsley Trust and St Christophers Hospice

When is the study starting and how long is it expected to run for?

April 2010 to April 2012

Who is funding the study?

The Kings Health Partners Biomedical Research Centre (UK)

Who is the main contact?

Dr Stirling Moorey

stirling.moorey@slam.nhs.uk

Contact information

Type(s)

Scientific

Contact name

Dr Stirling Moorey

Contact details

Maudsley Psychotherapy Service

Maudsley Hospital

Denmark Hill

London

United Kingdom

SE5 8AZ

+44 (0)203 228 2383

stirling.moorey@slam.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

CSA/10/022

Study information

Scientific Title

A comparison of brief cognitive behavioural therapy (CBT) and standard CBT in patients experiencing anxiety and depression in palliative care: a randomised controlled trial

Study objectives

A brief cognitive behavioural therapy (CBT) intervention will be as effective as standard CBT in patients attending a CBT outpatients clinic in a palliative care setting. The brief intervention will be as acceptable to patients and their carers as the full standard CBT package.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The South East London Research Ethics Committee (REC) 5, 28/05/2008, ref: 10/H0805/25

Study design

Single centre randomised controlled parallel group trial

Primary study design

Interventional

Secondary study design

Randomised parallel trial

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Anxiety and depression in patients with a range of cancers

Interventions

The standard CBT arm comprises 7 sessions of CBT, plus further sessions if necessary as specified in the CBT clinic operational policy. The brief CBT arm comprises 3 sessions combining assessment and intervention, then a booster session one month later. The extended assessment will consist of a rapid collaborative case conceptualisation, followed by the identification of key targets for rapid change. Brief interventions will be used to break maintaining cycles and regain previous adaptive coping strategies. A blueprint will be developed which will serve as a guide to how the patient, family and palliative care professionals can maintain and continue change. Therapy will be carried out at the hospice. Both therapists have had previous training in CBT and experience of CBT in palliative care. All sessions will be taped and therapists will receive weekly supervision from the Primary Investigator (Dr Moorey). Adherence to the model will be assessed using the Cognitive Therapy First Aid Rating Scale (CFARS).

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983):

This is a 14-item measure of mood designed for use with patients with physical illness. Seven items measure anxiety and seven depression. Its psychometric properties have been investigated in cancer patients, and it has been used successfully in previous trials in cancer patients.

All outcomes will be assessed at baseline, session 3, then at 10 and 16 weeks.

Secondary outcome measures

1. Impact of Event Scale - Revised (Horowitz 1979, Weiss & Marmar 1997, Mystakidou 2007):

This scale measures symptoms of intrusions and avoidance. A version developed by AJ Mitchell with specific reference to cancer will be used in this study

2. Brief COPE (Carver 1997):

This is a 28-item questionnaire that assesses 14 different ways people respond to stress.

3. Sense of Coherence Scale (Antonovsky 1987):

This scale measures 3 elements hypothesised to keep people well in the face of adversity: the ability to understand what is happening (comprehensibility), the ability manage the situation alone or with the help of a social network (manageability) and the ability to find meaning in the situation (meaningfulness).

4. Quality of Life Visual Analogue Scale:

Patients are asked to mark on a line how much they are distressed by the following symptoms: nausea, tiredness, pain and appetite problems.

5. The Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Oken et al. 1982):

The ECOG performance score has been used extensively in oncology research and is one of the most widely accepted measures of functional performance. The score ranges from 0 (fully active, able to carry on all pre-disease performance without restriction) to 5 (dead). At the mid-point, 3, the patient is capable of only limited self-care, confined to bed or chair for more than 50% of waking hours.

6. Cognitive Therapy First Aid Rating Scale (CFARS: Mannix et al 2006):

This is a validated measure of therapist competency and adherence.

All outcomes will be assessed at baseline, session 3, then at 10 and 16 weeks.

Overall study start date

01/11/2010

Completion date

01/04/2012

Eligibility

Key inclusion criteria

Adult patients (greater than or equal to 18 years) with ongoing and persistent distress /emotional problems (as measured by a Hospital Anxiety and Depression Scale [HADS] score of 8 or more on anxiety or depression) which are directly related to some aspect of the patient's disease/treatment and are not responding to the existing provision of psychological care within the hospice system. This includes:

1. Difficulties making treatment decisions or difficulties adhering to treatment
2. Anticipatory symptoms (e.g. nausea and vomiting)

3. Phobias that are interfering with treatment (e.g. needle or blood phobia)
4. Extreme emotion which appears to be disproportionate to reality
5. Post traumatic symptoms (flashbacks)
6. Body image issues, disfigurement or loss of function
7. Psychosexual problems
8. Extreme fears about the terminal stage of illness
9. Rigid thinking styles (all or nothing, overgeneralisation etc.)

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

56

Key exclusion criteria

1. Those who do not wish to have CBT
2. Psychosis or personality disorder
3. Very high suicide risk (psychiatric assessment required)
4. Moderate to severe drug and alcohol related problems
5. Patients already receiving psychological therapy or counselling
6. Patients who are not well enough to attend an outpatient clinic (e.g. unable to stay alert /awake for 50 mins, uncontrolled vomiting etc..)
7. Language or communication problems which prevent the patient from engaging in a talking treatment

Date of first enrolment

01/11/2010

Date of final enrolment

01/04/2012

Locations**Countries of recruitment**

England

United Kingdom

Study participating centre

Maudsley Hospital
London
United Kingdom
SE5 8AZ

Sponsor information

Organisation

Institute of Psychiatry (UK)

Sponsor details

c/o Jennifer Liebscher
R & D Governance and Delivery Manager
SLaM/IoP R & D Office
Room W1.08
London
United Kingdom
SE5 8AF

Sponsor type

Research organisation

Website

<http://www.iop.kcl.ac.uk/>

ROR

<https://ror.org/0220mzb33>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research (NIHR) (UK) - Biomedical Research Centre for Mental Health: Common Mental and Somatic Disorders Theme

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration